Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Disease Cluster Introduction 9
2.2 Symptoms 9
2.2.1 Migraine 9
2.2.2 Inflammatory pain and neuropathic pain 10
2.3 Diagnosis 10
2.4 Pathophysiology 10
2.4.1 Nociceptive pain transmission 10
2.4.2 Pain modulation in the brain 12
2.4.3 Inflammatory pain 13
2.4.4 Migraine 13
2.4.5 Neuropathic pain 14
2.5 Epidemiology 14
2.5.1 Migraine 14
2.5.2 Inflammatory pain 15
2.5.3 Neuropathic pain 16
2.6 Comorbidities and Complications 17
2.7 Treatment 17
2.7.1 Non-steroidal anti-inflammatory drugs 18
2.7.2 Opioid medications 18
2.7.3 Triptans 20
2.7.4 Other medications 20
2.7.5 Conclusion 21
3 Key Marketed Products 22
3.1 Celebrex (celecoxib) – Pfizer 22
3.2 Nucynta (tapentadol) – Depomed 24
3.3 Lyrica (pregabalin) – Pfizer 26
3.4 Exparel (bupivacaine) – Pacira 27
3.5 Voltaren (diclofenac sodium) – Novartis 28
3.6 Pennsaid (diclofenac sodium) – Horizon 29
3.7 Depakine (valproate sodium) – Daiichi Sankyo 30
3.8 Embeda ER (morphine sulfate + naltrexone) – Pfizer 31
3.9 Cymbalta (duloxetine hydrochloride) – Eli Lilly 32
3.10 Conclusion 34
4 Pipeline Landscape Assessment 35
4.1 Overview 35
4.2 Pipeline Development Landscape 35
4.3 Molecular Targets in the Pipeline 38
4.4 Clinical Trial Landscape 42
4.4.1 Failure Rate by Stage of Development, Indication and Molecule Type 43
4.4.2 Clinical Trial Duration by Stage of Development, Indication, and Molecule Type 46
4.4.3 Clinical Trial Size by Stage of Development, Indication and Molecule Type 48
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication and Molecule Type 50
4.5 Conclusion 53
4.6 Assessment of Key Pipeline Products 54
4.6.1 HTX-011 – Heron 54
4.6.2 Difelikefalin – Cara 55
4.6.3 Fremanezumab – Teva 56
4.6.4 Eptinezumab – Alder 57
4.6.5 Erenumab – Amgen and Novartis 58
4.6.6 Galcanezumab – Eli Lilly 59
4.6.7 Zilretta – Flexion 60
4.6.8 EMA-401 – Novartis 61
4.6.9 Conclusion 62
5 Multi-scenario Market Forecast to 2022 64
5.1 Overall Market Size 64
5.2 Generic Penetration 67
5.2.1 Generic Opioid Usage 68
5.3 Revenue Forecast by Molecular Target 73
5.3.1 Opioid Receptors 73
5.3.2 Serotonin Receptors 1B and 1D 74
5.3.3 Prostaglandin G/H Synthase (COX) 75
5.3.4 Calcitonin Gene Related Peptide Receptors 76
5.3.5 Multiple Targets 77
5.3.6 Ion Channels 78
6 Company Analysis and Positioning 80
6.1 Revenue and Market Share Analysis by Company 82
6.1.1 Teva – Company Set to Enter the Market and Secure Large Market Share by 2023 86
6.1.2 Pfizer – Key Patent Expiries to Drive Negative Growth 86
6.1.3 Pacira – Company to Secure a Large Market Share despite Small Product Portfolio 87
6.1.4 Novartis – Expansion of Pain Therapeutics Portfolio for the First Time since Voltaren 88
6.1.5 Amgen – Company Set to Enter Pain Market in Early Forecast Period and Achieve Rapid Growth 89
6.1.6 Allergan – Expansion of Product Portfolio to Drive Growth 90
6.1.7 Depomed – Revenue to Rise despite Upcoming Patent Cliff 91
6.1.8 Lilly – Lilly to Expand Position in Market as Patent for Cymbalta Expires 92
6.2 Company Landscape 93
6.3 Marketed and Pipeline Portfolio Analysis 94
7 Strategic Consolidations 97
7.1 Licensing Deals 97
7.1.1 Deals by Region, Value and Year 97
7.1.2 Deals by Indication 98
7.1.3 Deals by Stage of Development and Value 99
7.1.4 Deals by Molecule Type, Molecular Target and Value 100
7.1.5 Licensing Deals with Disclosed Values 101
7.2 Co-development Deals 103
7.2.1 Deals by Region, Value and Year 103
7.2.2 Deals by Indication 104
7.2.3 Deals by Stage of Development and Value 104
7.2.4 Deals by Molecule Type and Value 105
7.2.5 Co-development Deal with Disclosed Values 106
8 Appendix 107
8.1 References 107
8.2 List of Pipeline Products 110
8.3 Table of Epidemiology Forecast 142
8.4 Abbreviations 144
8.5 Methodology 145
8.5.1 Coverage 145
8.5.2 Secondary Research 145
8.5.3 Market Size and Revenue Forecasts 146
8.5.4 Pipeline Analysis 146
8.5.5 Competitive Landscape 147
8.6 Contact Us 147
8.7 Disclaimer 147